Immune reprogramming via PD-1 inhibition enhances early-stage lung cancer survival

Success of immune checkpoint inhibitors in advanced non-small-cell lung cancer (NSCLC) has invigorated their use in the neoadjuvant setting for early-stage disease. However, the cellular and molecular mechanisms of the early immune responses to therapy remain poorly understood. Through an integrated...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:JCI Insight
Main Authors: Markowitz, Geoffrey J., Havel, Lauren S., Crowley, Michael J.P., Ban, Yi, Lee, Sharrell B., Thalappillil, Jennifer S., Narula, Navneet, Bhinder, Bhavneet, Elemento, Olivier, Wong, Stephen T.C., Gao, Dingcheng, Altorki, Nasser K., Mittal, Vivek
Format: Artigo
Sprog:Inglês
Udgivet: American Society for Clinical Investigation 2018
Fag:
Research Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6101707/
https://ncbi.nlm.nih.gov/pubmed/29997286
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.96836
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker